AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00002665
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg/m2 IT or IV, d 2, 9, 16, and 23; Maximum 15 mg/admin
Trial: NCT01993212
Drug: Androxal 12.5 mg or 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01993212
Drug: AndroGel 1.62%
RxNorm normalized name: Androgel 1.62% Transdermal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01993212
Drug: Placebo Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01993212
Drug: Placebo Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01858532
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT00864890
Drug: CelexaTM 40 mg tablets, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Forest Labs formulated products under fed conditions
Trial: NCT02753881
Drug: whole liver lobe cTACE doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin CTACE administered in a whole liver lobe manner.
Trial: NCT03343067
Drug: estradiol/norethindrone acetate (E2/NETA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules
Trial: NCT01669928
Drug: Anti-hypertensive Medication -
RxNorm normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be taking their routine blood pressure lowering medication prescribed by their GP, different patients will be using different blood pressure lowering medication.~Dosing regimen either in the morning (between 06.00 and 11.00) or in the evening (between 18.00 and 23.00).
Trial: NCT03387683
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to match dapagliflozin
Trial: NCT01368432
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill placebo
Trial: NCT02753881
Drug: superselective cTACE doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin CTACE administered in a super-selective (close to the tumor) manner.
Trial: NCT02738632
Drug: Telmisartan/Amlodipine+Hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg 1 Tab.QD~Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg 1 Tab.QD
Trial: NCT02738632
Drug: Placebo for Hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01008150
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01008150
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02905656
Drug: Pharmacological
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine Replacement Therapy in the form of gum.
Trial: NCT01916967
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, given orally, once daily in the evening for 2 weeks
Trial: NCT04375618
Drug: Plain Collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A collagen membrane without FGF-2 will be used.
Trial: NCT00846287
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will inhale a placebo (nebulized saline) with no drug.
Trial: NCT03175354
Drug: ALX-101 Gel 1.5% and ALX-101 Gel Vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral application of ALX-101 Gel 1.5% and ALX-101 Gel Vehicle
Trial: NCT03175354
Drug: ALX-101 Gel 5% and ALX-101 Gel Vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral application of ALX-101 Gel 5% and ALX-101 Gel Vehicle
Trial: NCT01271114
Drug: Normal saline and norepinephrine
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline IV bolus 7mL/kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation above 10%; Norepinephrine drip (80 micrograms/mL) to keep MAP at least 70 mmHg
Trial: NCT02044835
Drug: Fu-zheng-qu-zhuo oral liquid
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fu-zheng-qu-zhuo oral liquid was composed of Ginseng, Astragalus, Angelica root, Tuckahoe, Rhubarb, etc. It was producted by manufacturing laboratory of Guang'anmen Hospital, China Academy of Chinese Medical Science (License code: 京药制字Z20063242)
Trial: NCT00986856
Drug: Fucidin® cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02787551
Drug: Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet Route of administration: oral If previously taken, doses to remain stable through the study.
Trial: NCT00753779
Drug: colesevelam HCl tablets, and simvastatin tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: colesevelam HCl tablets, 6/day simvastatin tablet, 1/day
Trial: NCT00753779
Drug: simvastatin tablets and colesevelam HCl placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin tablet, 1/day; Welchol placebo tablets, 6/day
Trial: NCT04383002
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iNO will be given at 160ppm for 6 hours, once a day, for 2 days
Trial: NCT02361190
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of 1ml aqueous nasal spray containing 7mg testosterone propionate
Trial: NCT02361190
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 1ml aqueous saline spray
Trial: NCT02218359
Drug: Amikacin Fosfomycin Inhalation Solution
RxNorm normalized name: amikacin Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the AFIS Inline System
Trial: NCT01878617
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Route of Administration (ROA): Intravenously (IV)
Trial: NCT02218359
Drug: Aerosolized placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for Days 1 -5 to be administered by aerosol using the eFlow Inline System.
Trial: NCT02218359
Drug: Amikacin Fosfomycin Inhalation Solution
RxNorm normalized name: amikacin Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label crossover for all patients Days 6-10
Trial: NCT01677559
Drug: MLN8237
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04807127
Drug: Targeted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TKI, administered as standard-of-care treatment
Trial: NCT00002582
Drug: CMF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002582
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002582
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002582
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002582
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04556773
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine: administered orally
Trial: NCT01541553
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Field treatment with vehicle gel once daily for 3 consecutive days.
Trial: NCT01218620
Drug: Gamma-Secretase Inhibitor RO4929097
RxNorm normalized name: .GAMMA.-OCTALACTONE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02634281
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
Trial: NCT03048461
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intradermal injections to an area of alopecia
Trial: NCT02693392
Drug: Oral hypoglycemic agents (pre-specified) [Metformin, Sulfonylurea]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving either of the following oral hypoglycemic agents~1. Sulfonylurea based oral hypoglycemic agents~2. Metformin based oral hypoglycemic agents~3. Metformin plus Sulfonylurea based oral hypoglycemic agents
Trial: NCT01872689
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to lebrikizumab will be administered via SC injection once every 4 weeks.
Trial: NCT00424801
Drug: Amiloride, hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 1 tbl. OD for 8 months
Trial: NCT05115578
Drug: Remifentanil 1 MG Injection [Ultiva]
RxNorm normalized name: remifentanil 1 MG Injection [Ultiva]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I TCI effect-site target infusion of 1.5 ng/ml of remifentanil.
Trial: NCT02939079
Drug: Placebo (for Fish Oil)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules to mimic Fish Oil 1 g capsules
Trial: NCT01697358
Drug: Optimal Medical Management (OMM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigator and subject will determine an individual OMM treatment plan, which should include non-investigational pharmacologic agents and/or therapies.
Trial: NCT02874287
Drug: Placebo Tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects are treated with oral placebo tablets 200mg twice daily for 20 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.
Trial: NCT00276874
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo; 0 mg; oral; daily
Trial: NCT00915356
Drug: AZD1305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (iv) single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
Trial: NCT00915356
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
Trial: NCT04150939
Drug: Immunotherapeutic Agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive standard of care immunotherapy
Trial: NCT03298373
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules that look like the 11β-MNTDC capsules but with no active ingredients.
Trial: NCT03298373
Drug: 11β-methyl-nortestosterone-dodecylcarbonate
RxNorm normalized name: 17-Ethynyl-18-methyl-19-nortestosterone
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 11β-MNTDC doses in castor oil/benzyl benzoate capsules (100 mg each) administered in 200 mg or 400 mg doses orally.
Trial: NCT02558387
Drug: BIBF1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib will be given orally at a dose of 200mg twice daily (bid) until progression or unacceptable toxicity.
Trial: NCT02463071
Drug: AZD0585
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1g soft capsule
Trial: NCT02463071
Drug: AZD0585 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1g soft capsule
Trial: NCT00600535
Drug: Stage 3: glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for 12 cycles (28 days/cycle).
Trial: NCT00600535
Drug: Stage 4: glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for up to 24 cycles (28 days/cycle).
Trial: NCT03773367
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
Trial: NCT02035501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04489459
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Tigecycline 100 mg IV infusion over 1 hour loading dose followed by maintenance dose 50 mg IV infusion over 1 hour q12
Trial: NCT00623025
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 to 9 capsules placebo per day
Trial: NCT01634763
Drug: LDK378
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02297191
Drug: Ropivicaine
RxNorm normalized name: Ropivicaine-Sufentanil Citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01470794
Drug: Toca FC
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01346969
Drug: EXC 001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose administered by injection four different times
Trial: NCT01346969
Drug: EXC 001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single reduced dose compared to Group 1 administered by injection at the same four time periods as Group 1
Trial: NCT01346969
Drug: EXC 001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single reduced dose compared to Groups 1 and 2 administered by injection at the same four time periods as Groups 1 and 2
Trial: NCT01346969
Drug: EXC 001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same sinlge dose as Group 1 administered by injection at the same four time periods as Groups 1, 2, and 3
Trial: NCT01978535
Drug: Iron infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg of intravenous iron sucrose supplied as Venofer (TM) with a maximum dose of 200mg. Iron sucrose will be diluted to 1 mg of elemental iron in 1 mL of NaCl 0.9% with a maximum volume of 210 mL.
Trial: NCT01658852
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00053092
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01175356
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01175356
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02867124
Drug: XR-NTX
RxNorm normalized name: Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vivitrol
Trial: NCT01433731
Drug: placebo for SHAPE (SHP-141)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical gelled solution
Trial: NCT01433731
Drug: SHAPE (SHP-141) 0.1% BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical gelled solution
Trial: NCT01433731
Drug: SHAPE (SHP-141) 0.5% BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical gelled solution
Trial: NCT01433731
Drug: SHAPE (SHP-141) 1.0% BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical gelled solution
Trial: NCT02674776
Drug: HuZhen Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients should take 4 tablet once and 3 times per day for 3 days.
Trial: NCT02674776
Drug: Placebo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients should take 4 tablet once and 3 times per day for 3 days.
Trial: NCT01687140
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take one pill a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
Trial: NCT03103581
Drug: BLI4700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLI4700 Bowel Preparation (Investigational Regimen)
Trial: NCT01937598
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients administered a single dose of placebo during a mixed meal challenge.
Trial: NCT00161486
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel 100 mg daily for 4 weeks
Trial: NCT00161486
Drug: Placebo Testosterone gel
RxNorm normalized name: testosterone Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo testosterone gel daily for 4 weeks
Trial: NCT02771509
Drug: ANG-3777
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/mL BB3, IV, 4 days in a row, first dose must be within 4 hours after surgery, the next three doses will be approx. 24 hours after the last dose
Trial: NCT02394483
Drug: F901318 tolerability
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolerability assessments
Trial: NCT02394483
Drug: F901318 pharmacokinetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetic assessments
Trial: NCT01788384
Drug: Clindamycin Phosphate / Benzoyl Peroxide Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
Trial: NCT01788384
Drug: Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
Trial: NCT01788384
Drug: Placebo (Vehicle Gel)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
Trial: NCT04680156
Drug: Previously treated with EN3835 up to 1.74 mg or Placebo in EN3835-210 or the pivotal phase 3 studies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment to be administered - Observational only
Trial: NCT00603785
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with chronic sinusitis and evidence of atopy and an elevated total IgE (\>30 and \<700 IU/ml) will be randomized to receive placebo treatment for 6 months.
Trial: NCT03882788
Drug: Fentanyl (high dose)
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl (narcotic anesthesia) maintenance will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr.
Trial: NCT03882788
Drug: Fentanyl (low dose)
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl (narcotic anesthesia) maintenance will be with fentanyl 2 mcg/kg/hr.
Trial: NCT04621565
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No hydrocortisone or other steroids are given before, during, and after the surgery, except that patients develop postoperative adrenal insufficiency. If a patient develops postoperative adrenal insufficiency, he/she needs to receive hydrocortisone treatment (20mg at 0800 and 20mg at 1600) for one month and then check the level of morning serum cortisol to decide if it is time to start the hydrocortisone taper program.
Trial: NCT04621565
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone sodium succinate is given on the operation day (100mg at 0800 \& 100mg at 2000), the postoperative day 1 (100mg at 0800 \& 50mg at 2000), and the postoperative day 2 (25mg at 0800). Hydrocortisone (po.) is then given starting from the afternoon of postoperative day 2 (20mg at 1600 and 0800) to the end of the first postoperative week, and 20mg at 0800 during the second postoperative week. This is called the hydrocortisone taper program. If a patient develops postoperative adrenal insufficiency, he/she needs to receive hydrocortisone treatment (20mg at 0800 and 20mg at 1600) for one month and then check the level of morning serum cortisol to decide if it is time to start the hydrocortisone taper program.
Trial: NCT04460456
Drug: SBT6050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses of SBT6050 in Part 1 and recommended dose in Part 2
Trial: NCT03698331
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-active dosage form
Trial: NCT02386306
Drug: GC021109
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01713270
Drug: drug
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agents, propafenone, amiodarone
Trial: NCT02116257
Drug: PCA regimen
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02250859
Drug: FMX101, Minocycline 4% foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMX101, Minocycline 4% foam to be applied twice daily for 16 consecutive days